{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:31Z","timestamp":1792087351402,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Health\u2010related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma post\u2010transplant, when disease symptoms are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed HRQoL in patients randomised to 26 cycles of MT (ixazomib vs placebo) in TOURMALINE\u2010MM3 (NCT02181413).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The characteristics at study entry were well\u2010balanced between ixazomib (n\u00a0=\u00a0386) and placebo (n\u00a0=\u00a0251) arms. At study entry, EORTC QLQ\u2010C30 and MY20 scores were high for functional scales and low for symptom scales and were comparable with those of the general population. Changes in subscale scores across intervals, analysed over 30 four\u2010week intervals using a linear mixed\u2010effects model, were generally small and similar between arms for the EORTC QLQ\u2010C30 Global Health Status\/QoL, Physical Functioning, and Pain subscales and EORTC QLQ\u2010MY20 Disease Symptoms subscale and Peripheral Neuropathy item. EORTC QLQ\u2010C30 Nausea\/Vomiting and Diarrhoea subscales were consistently worse for ixazomib than for placebo, in line with the ixazomib toxicity profile. Even when least\u2010squares mean differences between arms were statistically significant, none reached the established minimal important clinical difference of 10 in multiple myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In addition to improvement in progression\u2010free survival with ixazomib, HRQoL was maintained in both arms. Active treatment with ixazomib did not have an adverse impact on HRQoL.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13379","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T04:24:56Z","timestamp":1577420696000},"page":"443-458","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quality of life is maintained with ixazomib maintenance in post\u2010transplant newly diagnosed multiple myeloma: The TOURMALINE\u2010MM3 trial"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"first","affiliation":[{"name":"Oslo Myeloma Center Oslo University Hospital Oslo Norway"},{"name":"KG Jebsen Center for B cell malignancies University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V University Medical Hospital and National Center of Tumor Diseases University of Heidelberg Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Maisnar","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2014Hematology Charles University Hospital Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"Department of Hematology Charles University Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neils","family":"Abildgaard","sequence":"additional","affiliation":[{"name":"Department of Hematology Odense University Hospital University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rowlings","sequence":"additional","affiliation":[{"name":"Department of Hematology School of Medicine &amp; Public Health University of Newcastle Waratah New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Cain","sequence":"additional","affiliation":[{"name":"Statistical and Quantitative Sciences Takeda Pharmaceuticals Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[{"name":"Global Outcomes Research Takeda Pharmaceuticals Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveri","family":"Suryanarayan","sequence":"additional","affiliation":[{"name":"Oncology Clinical Research Takeda Pharmaceuticals Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Odom","sequence":"additional","affiliation":[{"name":"Biostatistics RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Gnanasakthy","sequence":"additional","affiliation":[{"name":"Patient\u2010Centered Outcomes Assessment RTI Health Solutions Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics Hematology &amp; Medical Oncology School of Medicine National and Kapodistrian University of Athens Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12012"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405016"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.89"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.256"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0177-6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2018-0004"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30366"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017186"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-451872"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12882"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-79"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01665.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0107"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01404.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.127860"},{"key":"e_1_2_8_20_1","unstructured":"EORTC.EORTC QLQ\u2010C30 Scoring Manual.2001.https:\/\/www.eortc.be\/qol\/files\/SCManualQLQ-C30.pdf. Accessed December 15 2018."},{"key":"e_1_2_8_21_1","unstructured":"EORTC.Scoring of the EORTC QLQ\u2010C30 summary score.2018.https:\/\/qol.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/scoring_of_the_qlq-c30_summary_score.pdf. Accessed December 15 2018."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_2_8_24_1","unstructured":"ScottNW FayersPM AaronsonNK et al.EORTC QLQ\u2010C30 reference values.2008.http:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf. Accessed November 1 2018."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318267cf84"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074534"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.537.537"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13231"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.6480"},{"key":"e_1_2_8_30_1","unstructured":"Food and Drug Administration.US Department of Health and Human Services. Guidance for industry patient\u2010reported outcome measures: use in medical product development to support labeling claims.2009.https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf. Accessed November 2 2018."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.006"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw425"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182a46bcf"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-496"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23753"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3446-y"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T04:25:46Z","timestamp":1693628746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/ejh.13379"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13379","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,22]]},"assertion":[{"value":"2019-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}